PHARE: One-Year Trastuzumab Remains Standard for HER2-Positive Breast Cancer

A 6-month regimen of treatment with trastuzumab for HER2-positive breast cancer failed to show noninferiority with the standard 12-month treatment regimen after 3.5 years of follow-up in the open-label, randomized, phase III PHARE trial.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news